Evotec SE ADR (EVO)vsViatris Inc (VTRS)
EVO
Evotec SE ADR
$1.96
0.00%
HEALTHCARE · Cap: $696.56M
VTRS
Viatris Inc
$16.23
0.00%
HEALTHCARE · Cap: $18.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 1955% more annual revenue ($14.74B vs $717.28M). VTRS leads profitability with a -2.8% profit margin vs -27.5%. VTRS appears more attractively valued with a PEG of 1.05. VTRS earns a higher WallStSmart Score of 48/100 (D+).
EVO
Hold40
out of 100
Grade: D
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.8%
Fair Value
$34.30
Current Price
$1.96
$32.34 discount
Margin of Safety
-86.3%
Fair Value
$8.66
Current Price
$16.23
$7.57 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -28.0% — below average capital efficiency
Revenue declined 16.2%
4.9% revenue growth
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EVO
The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bear Case : EVO
The primary concerns for EVO are EPS Growth, Market Cap, Return on Equity.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.
Key Dynamics to Monitor
EVO carries more volatility with a beta of 1.26 — expect wider price swings.
VTRS is growing revenue faster at 4.9% — sustainability is the question.
VTRS generates stronger free cash flow (677M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VTRS scores higher overall (48/100 vs 40/100). EVO offers better value entry with a 89.8% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evotec SE ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?